
A clinical trial found that FF/UMEC/VI significantly reduced persistent cough in asthma patients over six weeks (p = 0.006). It improved ACQ-5 scores, lung function, and peak expiratory flow without notable adverse effects. The randomized, double-blind study enrolled patients from June 2022 to December 2023, comparing FF/UMEC/VI to placebo. Results showed a rapid and significant therapeutic effect, supporting its use in managing asthma-related cough.
Like
Save
Share